 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Phase classification: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Jul 14, 2023
P1, N=56, Terminated, Sponsor: Ipsen
Phase classification: P1/2 --> P1
- | clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Dec 23, 2022
P1/2, N=56, Terminated, Sponsor: Ipsen
Phase classification: P1/2 --> P1 N=412 --> 56 | Trial completion date: Dec 2023 --> Oct 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Oct 2022; Sponsor terminated the study due to strategic considerations
- ||| clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Enrollment closed: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Apr 18, 2022
P1/2, N=412, Active, not recruiting, Sponsor: Ipsen
N=412 --> 56 | Trial completion date: Dec 2023 --> Oct 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Oct 2022; Sponsor terminated the study due to strategic considerations Recruiting --> Active, not recruiting
- | clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Journal: Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay. (Pubmed Central) - Nov 10, 2021
Interestingly, reduced dimerization was also observed with an SV2 mutant variant of HA. Overall, the results suggest that the FCS & TIRF receptor dimerization assay can assess FGFR dimerization with known and novel ligands and support a model wherein H/A, either directly or indirectly, interacts with FGFRs and induces receptor dimerization.
- |||| clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Enrollment open: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Apr 1, 2021
P1/2, N=424, Recruiting, Sponsor: Ipsen
Overall, the results suggest that the FCS & TIRF receptor dimerization assay can assess FGFR dimerization with known and novel ligands and support a model wherein H/A, either directly or indirectly, interacts with FGFRs and induces receptor dimerization. Suspended --> Recruiting
- |||||| clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Trial suspension: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Mar 1, 2021
P1/2, N=424, Suspended, Sponsor: Ipsen
Suspended --> Recruiting Recruiting --> Suspended
- |||| clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
Enrollment open: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Feb 25, 2021
P1/2, N=424, Recruiting, Sponsor: Ipsen
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ||||| clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
New P1/2 trial: LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - Feb 3, 2021
P1/2, N=424, Not yet recruiting, Sponsor: Ipsen
- ||||| Dysport (abobotulinumtoxinA) / Ipsen, clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen
New P1/2 trial: A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb (EUDRACT) - Apr 30, 2020
P1/2, N=209, Ongoing, Sponsor: Ipsen Innovation